Abstract:9035 Background: Tumor angiogenesis could be induced by activation of HER2 receptor, and currently, there is lack of clinical evidence of anti-HER2 tyrosine kinase inhibitors (TKIs) combined with antiangiogenic therapy for HER2-mutant or amplified non-small cell lung cancer (NSCLC). We conducted a study to explore the efficacy and safety of a pan-ErbB inhibitor pyrotinib combined with apatinib for metastatic NSCLC patients harboring HER2 amplification or activating mutations. Methods: This was a single-center, single-arm phase II study with Simon’s optimal two-stage design. Metastatic NSCLC patients with ECOG scores of 0-1 and harboring primary HER2 amplification, exon 20 insertion or activating missense mutations who had failed to prior chemotherapies or anti-HER2 TKIs were eligible to be enrolled. All patients received oral pyrotinib (400mg once daily) combined with apatinib (250mg once daily) therapy. The primary endpoint was objective response rate (ORR), and second endpoints included progression-free survival (PFS), duration of response (DoR), disease control rate (DCR), overall survival (OS) and safety. Results: Between March 5, 2019, and December 1, 2020, 33 metastatic NSCLC patients with HER2 alterations were enrolled, including exon 20 insertions (A775_G776insYVMA, 20/33; P780_Y781insGSP, 6/33; other variants, 2/33), missense mutations (3/33), and primary HER2 amplification (2/33). Seventeen patients (51.5%) were pretreated with first-line platinum-based chemotherapies or anti-HER2 TKIs, and the remaining had received at least 2 lines of prior therapies (range, 2-6). At the last follow-up time January 23, 2021, the overall ORR and DCR were 45.5% (15/33) and 93.9% (31/33), respectively. The median PFS was 6.8 (95%CI: 5.4-8.2) months. The median DoR and OS were 5.3 (95%CI: 0-11.8) and 12.9 (95%CI: 8.6-17.2) months, respectively. The mPFS was significantly longer in patients who received second-line pyrotinib combined with apatinib therapy than those in third- or above-line settings (9.8 vs. 5.3 months, P = 0.018, HR = 0.281 [95%CI: 0.098-0.807]). Although pyrotinib combined with apatinib therapy showed similar ORRs in patients with presence (46.2%, 6/13) or absence (45.0%, 9/20) of brain metastases, and those in second-line (47.1%, 8/17) or above-line settings (43.8%, 7/16). Common treatment-related adverse events (AEs) were grade 1-2, mainly including diarrhea (90.9%), hypertension (72.7%), asthenia (63.6%), anorexia (54.5%) and nausea (51.5%). Grade 3 AEs were diarrhea (3.0%) and hypertension (9.1%). No grade 4 or 5 AE or treatment-related deaths were reported. Conclusions: Pyrotinib combined with apatinib showed potent anti-tumor activity and acceptable safety profile in metastatic NSCLC with HER2 amplification or activating mutations. Clinical trial information: ChiCTR1900021684.

Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study

P1.12-01 A Single-Arm Multi-Center Phase II Study of Apatinib in Patients with ES-SCLC after Second/Third-Line Chemotherapy

Efficacy and Safety for Apatinib Combined with Oxaliplatin and S1 in Initially Treated Metastatic Gastric Cancer: A Single-Center Observational Study.

A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy

A Phase II, Multicenter, Placebo-Controlled Trial of Apatinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) after Two Previous Treatment Regimens.

Low Dose of Apatinib in Treating Chemotherapy and EGFR-TKI Refractory Non-Small Cell Lung Cancer A Case Report

Combination of Apatinib and Docetaxel in Treating Advanced Non-Squamous Non-Small Cell Lung Cancer Patients with Wild-Type EGFR: a Multi-Center, Phase II Trial

Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced Non-Small-cell Lung Cancer.

Phase I Study of Apatinib Combined with Docetaxel in EGFR-negative Advanced Non-Small Cell Lung Cancer (NSCLC).

Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results from a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial.

Apatinib Alone or Combined with Radiation Therapy As a Salvage Treatment in Advanced Non-Small Cell Lung Cancer Failed from Two or More Lines of Prior Chemotherapy or Molecular Targeted Therapy

P1.01-90 A Pilot Trial Assessing Apatinib Combined with Docetaxel (DTX) As Second-Line Chemotherapy for EGFR Negative Advanced NSCLC)

P1.12-03 A Prospective Study of Apatinib in Advanced Small Cell Lung Cancer Patients Failed from Two or More Lines of Chemotherapy

P2.01-017 Study on the Effect of Apatinib Salvage Treatment of Advanced Non-Small Cell Lung Cancer

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients with Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review

Clinical efficacy of Apatinib combined with Epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI) in nonsmall cell lung cancer after EGFR-TKI resistance

Apatinib in the treatment of advanced non-small-cell lung cancer: A meta-analysis.

Efficacy and safety of pan-ErbB inhibitor pyrotinib combined with antiangiogenic agent apatinib for HER2-mutant or amplified metastatic NSCLC: A phase II clinical study.

The Efficacy and Safety of Apatinib in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Trial

Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study